Genomic Services Research Program
Recruiting
Background: Genes are the instructions a person s body uses to function. Genome sequencing reads through all of a person s genes. Everyone has many gene variants, and most do not cause disease. Some gene variants called secondary findings may be important for a person s health even if they are not related to the reason why a person had genome sequencing done. Researchers want to learn more about what it means to have a secondary finding. Objectives: To learn about how gene variants may affect... Read More
Gender:
ALL
Ages:
Between 1 month and 105 years
Trial Updated:
06/26/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Colon Cancer, Breast Cancer
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
Recruiting
The purpose of the study is to evaluate the long-term safety and tolerability of brivaracetam.
Gender:
ALL
Ages:
1 month and above
Trial Updated:
06/26/2025
Locations: Ep0156 259, Hawthorne, New York +35 locations
Conditions: Epilepsy
NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks
Recruiting
The goal of this clinical trial is to test an enhanced version of the National Diabetes Prevention Program (NDPP-NextGen) that is tailored to young women in childbearing years. The investigators will recruit 360 women aged 18-39 years with overweight/obesity who are not currently pregnant, but likely to conceive within 24 months. Women will be randomized to NDPP-NextGen or a usual care control group. The NDPP-NextGen group will participate in the adapted NDPP online group class across 12 months,... Read More
Gender:
FEMALE
Ages:
Between 18 years and 39 years
Trial Updated:
06/26/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Overweight or Obesity
Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate
Recruiting
Background: At least 30% of Americans have fatty liver disease. This means that they store too much fat in the liver. At the moment lifestyle changes are the only way to treat this problem. Objective: To test how (1) a low-carbohydrate diet and (2) a supplement called nicotinamide riboside (NR) affect how a person s body uses dietary fat. Eligibility: Men aged 18 to 65 and women aged 18 to 50 who are healthy volunteers with a body mass index (height to weight ratio) of 25 or more. Adults wi... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/26/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Overweight, Obesity
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
Recruiting
This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with cGVHD.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/26/2025
Locations: Mayo Clinic Hospital, Phoenix, Arizona +69 locations
Conditions: Chronic Graft-versus-host-disease
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Recruiting
This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) or younger patients who are considered unfit for standard treatment, and who have an abnormal change (mutation) in the IDH2 gene. This gene mutation can cause AML to grow and spread. This trial is being done to see if adding enasidenib to the usual treatment can help mo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California +51 locations
Conditions: Acute Myeloid Leukemia
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Recruiting
GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Elite Clinical Studies, LLC, Phoenix, Arizona +100 locations
Conditions: Hypertension
Long-Term Follow-up of People Undergoing Hematopoietic Stem Cell Transplantation
Recruiting
Background: People who have had an allogeneic hematopoietic stem cell transplant (HCT) have bone marrow or an immune system that is damaged. They get stem cells from a donor who is a relative. Researchers want to study stem cell donors and recipients to learn about the long-term effects of HCT. They want to learn how the stem cells change and how to improve their ability to fight cancer. Objective: To provide long-term follow-up care for people who underwent or will undergo HCT. To collect da... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
06/26/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Hematopoietic Stem Cell Transplantation, Tissue Donors
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Recruiting
Background: Autism spectrum disorder (ASD) is a complex neurodevelopmental syndrome. Researchers think brain development may be controlled by gamma-aminobutyric acid (GABA). They want to learn how abnormalities in the GABA system may contribute to ASD. Objective: To see if repetitive transcranial magnetic stimulation (rTMS) creates short-term changes in how different parts of the brain communicate. Eligibility: Right-handed people ages 11-17 with ASD, and healthy volunteers ages 18-25. Des... Read More
Gender:
ALL
Ages:
Between 11 years and 25 years
Trial Updated:
06/26/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Autism Spectrum Disorder
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Recruiting
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 posi... Read More
Gender:
ALL
Ages:
Between 5 years and 60 years
Trial Updated:
06/26/2025
Locations: USA Health Strada Patient Care Center, Mobile, Alabama +347 locations
Conditions: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Recruiting
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +487 locations
Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
A Study Evaluating APG777 in Atopic Dermatitis
Recruiting
This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants ra... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Investigational Site #14, Fountain Valley, California +83 locations
Conditions: Atopic Dermatitis